complement component 4 binding protein alphaGenealiases: C4BP · PRP
Q-omics provides the consensus-scored C4BPA profile across patient tissues and cancer cell-line models. C4BPA expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, C4BPA is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, C4BPA RNA expression shows 18,330 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KICH, and LSCC as cancer lineages where C4BPA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4BPA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4BPA survival associations across molecular data types. C4BPA RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4BPA RNA expression–survival associations across cancer types. High C4BPA expression shows unfavorable associations in KIRC, LUSC and ESCA, but favorable associations in UCEC, LIHC and OV. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for C4BPA RNA expression.
This table summarizes C4BPA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C4BPA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4BPA shows lower tumor expression in KICH, LUAD, LUSC, BRCA and CHOL and higher tumor expression in KIRP. The KICH box plot shows higher C4BPA RNA expression in normal versus tumor tissue (log2 FC = −0.274, t-test p < 0.001).
This table shows molecular features associated with C4BPA in patient tissues and cancer cell lines. In patient samples, C4BPA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C4BPA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LIVER.
